ANTIBODIES FOR TREATMENT OF INFECTIONS AND DISEASES ASSOCIATED WITH Clostridium difficile

摘要

1. An isolated antibody or antigen-binding fragment thereof which (a) specifically binds C. difficile toxin A and which cross-hair competes for binding to C. difficile toxin A with a monoclonal antibody produced by a hybridoma cell line deposited under accession number ATCC PTA-9692, PTA-9694 or PTA-9888, and / or which (b) specifically binds to an epitope of C. difficile toxin A determined by a monoclonal antibody produced by a hybridoma cell line deposited under accession number ATCC PTA-9692, PTA-9694 or PTA-9888.2 . An antibody or antigen binding fragment thereof according to claim 1, wherein the monoclonal antibody or antigen binding fragment thereof is in a chimeric or humanized form. An isolated antibody or antigen binding fragment thereof which (a) specifically binds C. difficile Toxin B and which cross-competes for binding to C. difficile Toxin B with a monoclonal antibody produced by a hybridoma cell line deposited under accession number ATCC PTA-9693, and / or which (b) specifically binds to an epitope of C. difficile Toxin B determined by a monoclonal antibody produced by a hybridoma cell line deposited under accession number ATCC PTA-9693.4. An antibody or antigen binding fragment thereof according to claim 3, wherein the monoclonal antibody or antigen binding fragment thereof is in a chimeric or humanized form. Monoclonal antibody RA-39 (access no. ATCC PTA-9692) or its antigen-binding fragment. 6. Monoclonal antibody RA-50 (access no. ATCC PTA-9694) or its antigen-binding fragment. 7. Monoclonal antibody RA-38 (access no. ATCC PTA-9888) or its antigennegative fragment. 8. Monoclonal